238 related articles for article (PubMed ID: 9603075)
1. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy.
Shatz DV; Schinsky MF; Pais LB; Romero-Steiner S; Kirton OC; Carlone GM
J Trauma; 1998 May; 44(5):760-5; discussion 765-6. PubMed ID: 9603075
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively.
Shatz DV; Romero-Steiner S; Elie CM; Holder PF; Carlone GM
J Trauma; 2002 Dec; 53(6):1037-42. PubMed ID: 12478024
[TBL] [Abstract][Full Text] [Related]
3. IgG subclass antibody responses to pneumococcal polysaccharide vaccine in splenectomized, otherwise normal, individuals.
Aaberge IS; Michaelsen TE; Heier HE
Scand J Immunol; 1990 Jun; 31(6):711-6. PubMed ID: 2356437
[TBL] [Abstract][Full Text] [Related]
4. Serum antibody responses to vaccination with 23-valent pneumococcal vaccine in splenectomized patients.
Reinert RR; Kaufhold A; Kühnemund O; Lütticken R
Zentralbl Bakteriol; 1994 Nov; 281(4):481-90. PubMed ID: 7727895
[TBL] [Abstract][Full Text] [Related]
5. Timing of vaccination does not affect antibody response or survival after pneumococcal challenge in splenectomized rats.
Schreiber MA; Pusateri AE; Veit BC; Smiley RA; Morrison CA; Harris RA
J Trauma; 1998 Oct; 45(4):692-7; discussion 697-9. PubMed ID: 9783606
[TBL] [Abstract][Full Text] [Related]
6. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.
Romero-Steiner S; Musher DM; Cetron MS; Pais LB; Groover JE; Fiore AE; Plikaytis BD; Carlone GM
Clin Infect Dis; 1999 Aug; 29(2):281-8. PubMed ID: 10476727
[TBL] [Abstract][Full Text] [Related]
7. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
Yu X; Gray B; Chang S; Ward JI; Edwards KM; Nahm MH
J Infect Dis; 1999 Nov; 180(5):1569-76. PubMed ID: 10515817
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
9. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
10. IgM and IgG response to pneumococcal polysaccharide vaccine in normal individuals and individuals splenectomized due to trauma.
Aaberge IS; Heier HE; Hem E; Giercksky KE; Groeng EC
Acta Pathol Microbiol Immunol Scand C; 1984 Feb; 92(1):11-6. PubMed ID: 6711306
[TBL] [Abstract][Full Text] [Related]
11. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.
Zielen S; Bühring I; Strnad N; Reichenbach J; Hofmann D
Infect Immun; 2000 Mar; 68(3):1435-40. PubMed ID: 10678957
[TBL] [Abstract][Full Text] [Related]
13. Opsonic and antibody responses to pneumococcal polysaccharide types 6A, 19F and 23F after vaccination of immunocompromised patients.
Braconier JH; Pedersen FK; Odeberg H; Rosén C
Scand J Infect Dis; 1984; 16(2):161-7. PubMed ID: 6740247
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
15. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Martinez JE; Romero-Steiner S; Pilishvili T; Barnard S; Schinsky J; Goldblatt D; Carlone GM
Clin Diagn Lab Immunol; 1999 Jul; 6(4):581-6. PubMed ID: 10391867
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytic assay.
Kim KH; Seoh JY
J Korean Med Sci; 1999 Oct; 14(5):475-9. PubMed ID: 10576141
[TBL] [Abstract][Full Text] [Related]
17. Improved antibody responses to delayed pneumococcal vaccination in splenectomized rats.
Werner AM; Solis MM; Vogel R; Southerland SS; Ashley AV; Floyd JC; Brown C; Ashley DW
Am Surg; 1999 Sep; 65(9):844-7; discussion 847-8. PubMed ID: 10484087
[TBL] [Abstract][Full Text] [Related]
18. Prevention of pneumococcal bacteremia by immunization with type 6 pneumococcal capsular polysaccharide vaccine in splenectomized rats.
Iinuma H; Okinaga K
J Infect Dis; 1989 Jul; 160(1):66-75. PubMed ID: 2732517
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.
Pomat WS; Lehmann D; Sanders RC; Lewis DJ; Wilson J; Rogers S; Dyke T; Alpers MP
Infect Immun; 1994 May; 62(5):1848-53. PubMed ID: 8168948
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.
Yu X; Sun Y; Frasch C; Concepcion N; Nahm MH
Clin Diagn Lab Immunol; 1999 Jul; 6(4):519-24. PubMed ID: 10391854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
